SIRT1/HIF-1α pathway

The SIRT1/HIF-1α pathway is a signaling axis in which the NAD⁺-dependent deacetylase Sirtuin 1 (Sirt1) regulates the stability and transcriptional activity of Hypoxia-inducible factor 1-alpha (HIF-1α), linking cellular energy and redox state to the response to low oxygen. Sirt1 senses the NAD⁺/NADH ratio and deacetylates histone and non-histone substrates, including transcription factors such as FOXO3 and TP53. HIF-1α is the oxygen-labile subunit of the HIF-1 heterodimer: under normoxia it is hydroxylated by prolyl hydroxylases and degraded via the von Hippel-Lindau ubiquitin ligase, whereas under hypoxia it is stabilized, dimerizes with HIF-1β, and drives transcription of genes governing glycolysis, angiogenesis, and cell survival, notably VEGF and the glycolytic enzyme PKM2. Because Sirt1 activity depends on NAD⁺ and hypoxic metabolic reprogramming shifts NAD⁺ availability, the two arms of the axis are reciprocally coupled, making the pathway a node where metabolic supply, oxygen sensing, and gene expression are integrated.

This position at the interface of metabolism and stress signaling makes the pathway relevant across ischemic, inflammatory, fibrotic, metabolic, and neoplastic conditions, and both arms are pharmacologically tractable. In cerebral ischemia and ischemia-reperfusion injury, HIF-1α stabilization influences angiogenesis, blood–brain barrier integrity, and matrix metalloproteinase-9 activity, while Sirt1 activation is associated with reduced oxidative stress and apoptosis through effects on reactive oxygen species, superoxide dismutase, catalase, glutathione, heme oxygenase 1, and caspase-3. Sirt1 signaling also restrains NLRP3 inflammasome activation and the downstream caspase-1–dependent release of IL-1β and IL-18, a mechanism invoked in arthritis, steatohepatitis, and neuroinflammation, and it intersects with TGF-β1/SMAD signaling in fibrosis and with Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/mTOR and GSK-3β signaling in cell survival and metabolic adaptation. In tumors, HIF-1α-driven glycolysis and angiogenesis contribute to therapy resistance and shape responses to modalities such as photodynamic and photochemotherapy and to cytotoxic agents including doxorubicin and cisplatin. Interventions used to probe or manipulate the axis include Sirt1 activators such as resveratrol, NAD⁺ precursors such as nicotinamide mononucleotide, and a range of plant-derived compounds and HIF-directed agents.